[holding answer 4 June 2007]: All primary care trusts (PCTs) are funding photodynamic therapy treatment for patients with both the wholly classic and predominantly classic forms of wet age-related macular degeneration, in line with guidance from the National Institute for Health and Clinical Excellence (NICE).
NICE is currently carrying out an appraisal of Lucentis and Macugen, which are now both licensed for the treatment of wet age-related macular degeneration, and final guidance is due to be published in September 2007.
Where guidance from NICE is not yet available, PCTs are expected to apply local arrangements for the managed introduction of new technologies. These arrangements should include an assessment of the available evidence.